Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: Implications for cancer therapy

Nuclear Medicine and Biology

Volumn 39, Issue 2, 2012, Pages 187-197

  Nguyen, Kim ^a,b   Parry, Jesse J ^c   Rogers, Buck E ^a,c   Anderson, Carolyn J ^a,b,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Agonist; Antagonist; Copper 64; P53; Somatostatin

Indexed keywords

4 11 BIS(CARBOXYMETHYL) 1,4,8,11 TETRAAZABICYCLO[6.6.2]HEXADECANE; 4 11 BIS(CARBOXYMETHYL) 1,4,8,11 TETRAAZABICYCLO[6.6.2]HEXADECANE SST2 ANT CU 64; 4 11 BIS(CARBOXYMETHYL) 1,4,8,11 TETRAAZABICYCLO[6.6.2]HEXADECANE Y3 TATE CU 64; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CHELATING AGENT; COPPER 64; CYCLIC AMP; HEXADECANE; PROTEIN P53; RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR AGONIST; SOMATOSTATIN RECEPTOR ANTAGONIST; TETRAXETAN; TETRAXETAN Y3 TATE CU 64; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOMA CELL; CELL LINE; CELL NUCLEUS; CELL STRAIN HCT116; CELL TRANSPORT; CELLULAR DISTRIBUTION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG SCREENING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; ISOTOPE LABELING; MOLECULAR IMAGING; RADIOTHERAPY; RECEPTOR BINDING; TUMOR CELL;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; COORDINATION COMPLEXES; COPPER RADIOISOTOPES; HUMANS; PEPTIDES; RECEPTORS, SOMATOSTATIN; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84856340905     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.08.006     Document Type: Article

References (43)

1. Weiner R.E., Thakur M.L. Radiolabeled peptides in oncology. BioDrugs 2005, 19:145-163.
2. Kulaksiz H., Eissele R., Rossler D., Schulz S., Hollt V., Cetin Y., et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002, 50:52-60.
3. Reubi J.C., Waser B., Schaer J.C., Laissue J.A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001, 28:836-846.
4. Janson E.T., Stridsberg M., Gobl A., Westlin J.E., Oberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 1998, 58:2375-2378.
5. Hofland L.J., Liu Q., Van Koetsveld P.M., Zuijderwijk J., Van Der Ham F., De Krijger R.R., et al. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab 1999, 84:775-780.
6. Schulz S., Pauli S.U., Handel M., Dietzmann K., Firsching R., Hollt V. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 2000, 6:1865-1874.
7. Traub T., Petkov V., Ofluoglu S., Pangerl T., Raderer M., Fueger B.J., et al. 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med 2001, 42:1309-1315.
8. Schulz S., Schmitt J., Quednow C., Roessner A., Weise W. Immunohistochemical detection of somatostatin receptors in human ovarian tumors. Gynecol Oncol 2002, 84:235-240.
9. Kikutsuji T., Harada M., Tashiro S., Li S., Moritani M., Yamaoka T., et al. Expression of somatostatin receptor subtypes and growth inhibition in human exocrine pancreatic cancers. J Hepatobiliary Pancreat Surg 2000, 7:496-503.
10. Papotti M., Kumar U., Volante M., Pecchioni C., Patel Y.C. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxford) 2001, 54:641-649.
11. Reubi J.C., Schar J.C., Waser B., Wenger S., Heppeler A., Schmitt J.S., et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000, 27:273-282.
12. Bass R.T., Buckwalter B.L., Patel B.P., Pausch M.H., Price L.A., Strand J., et al. Identification and characterization of novel somatostatin antagonists. Mol Pharmacol 1996, 50:709-715.
13. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998, 58:437-441.
14. 3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001, 92:628-633.
15. 3-octreotate using a cross-bridged macrocyclicchelator. Clin Cancer Res 2004, 10:8674-8682.
16. 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors. J Nucl Med 2008, 49:1819-1827.
17. 64Cu-labeled chelator-somatostatin conjugates in an SSTr2-transfected human tumor cell line. J Nucl Med 2007, 48:1390-1396.
18. Wang M., Caruano A.L., Lewis M.R., Meyer L.A., Vander Waal R.P., Anderson C.J. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res 2003, 63:6864-6869.
19. 3-octreotate.A new somatostatin analog with improved target tissue uptake. Nucl Med Biol 1999, 26:267-273.
20. Komarova E.A., Gudkov A.V. Suppression of p53: a new approach to overcome side effects of antitumor therapy. Biochemistry (Mosc) 2000, 65:41-48.
21. Sebastian S., Azzariti A., Silvestris N., Porcelli L., Russo A., Tommasino M., et al. p53 as the main traffic controller of the cell signaling network. Front Biosci 2010, 15:1172-1190.
22. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat Rev 2002, 2:594-604.
23. Eiblmaier M., Meyer L.A., Anderson C.J. The role of p53 in the trafficking of copper-64 to tumor cell nuclei. Cancer Biol Ther 2008, 7:63-69.
24. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
25. Roth A., Kreienkamp H.J., Nehring R.B., Roosterman D., Meyerhof W., Richter D. Endocytosis of the rat somatostatin receptors: subtype discrimination, ligand specificity, and delineation of carboxy-terminal positive and negative sequence motifs. DNA Cell Biol 1997, 16:111-119.
26. McCarthy D.W., Shefer R.E., Klinkowstein R.E., Bass L.A., Margenau W.H., Cutler C.S., et al. The efficient production of high specific activity Cu-64 using a biomedical cyclotron. Nucl Med Biol 1997, 24:35-43.
27. Wong E.H., Weisman G.R., Hill D.C., Reed D.P., Rogers M.E., Condon J.P., et al. Synthesis and characterization of cross-bridged cyclams and pendant-armed derivatives and structural studies of their copper(II) complexes. J Am Chem Soc 2000, 122:10561-10572.
28. Achilefu S., Jimenez H.N., Dorshow R.B., Bugaj J.E., Webb E.G., Wilhelm R.R., et al. Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents. J Med Chem 2002, 45:2003-2015.
29. Parry J.J., Eiblmaier M., Andrews R., Meyer L.A., Higashikubo R., Anderson C.J., et al. Characterization of somatostatin receptor subtype 2 expression in stably transfected A-427 human cancer cells. Mol Imaging 2007, 6:56-67.
30. Wadas T.J., Anderson C.J. Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64. Nat Protoc 2006, 1:3062-3068.
31. 3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res 1999, 5:3608-3616.
32. Schottelius M., Poethko T., Herz M., Reubi J.C., Kessler H., Schwaiger M., et al. First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res 2004, 10:3593-3606.
33. Capello A., Krenning E., Bernard B., Reubi J.C., Breeman W., de Jong M. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2005, 32:1288-1295.
34. Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 2006, 103:16436-16441.
35. Koenig J.A., Kaur R., Dodgeon L., Edwardson J.M., Humphrey P.P.A. Fates of endocytosedsomatostatin sst2 receptors and associated agonists. Biochem J 1998, 336:291-298.
36. Hukovic N., Panetta R., Kumar U., Patel Y.C. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTr1-5): subtype selective internalization or upregulation. Endocrinology 1996, 137:4046-4049.
37. Eberle A.N., Mild G., Froidevaux S. Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors. J Recept Signal Transduct Res 2004, 24:319-455.
38. Cescato R., Loesch K.A., Waser B., Macke H.R., Rivier J.E., Reubi J.C., et al. Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Mol Endocrinol 2010, 21:240-249.
39. Liu Q., Cescato R., Dewi D.A., Rivier J., Reubi J., Schonbrunn A. Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Mol Pharmacol 2005, 68:90-101.
40. Hornick C.A., Anthony C.T., Hughey S., Gebhardt B.M., Espenan G.D., Woltering E.A. Progressive nuclear translocation of somatostatin analogs. J Nucl Med 2000, 41:1256-1263.
41. Apelgot S., Coppey J., Gaudemer A., Grisvard J., Guille E., Sasaki I., et al. Similar lethal effect in mammalian cells for two radioisotopes of copper with different decay schemes, Cu-64 and Cu-67. Int J Radiat Biol 1989, 55:365-384.
42. Hainaut P., Rolley N., Davies M., Milner J. Modulation by copper of p53 conformation and sequence-specific DNA binding: role for Cu(II)/Cu(I) redox mechanism. Oncogene 1995, 10:27-32.
43. Vanlandingham J.W., Tassabehji N.M., Somers R.C., Levenson C.W. Expression profiling of p53-tartet genes in copper-mediated neuronal apoptosis. Neuromolecular Med 2005, 7:311-324.